Heart failure was not defined as a component of MACE and was not adjudicated but was analyzed separately.
All components of this composite outcome were fully adjudicated by an independent end point committee.
Each component of the primary efficacy end point was independently adjudicated by the blinded Clinical Events Committee (for clinically driven target lesion revascularization) or by the core laboratories (for restenosis).
Potential GI endpoint events were adjudicated by an independent, blinded, expert GI events adjudication committee that evaluated whether the suspected GI event met predefined criteria for a component of the composite GI endpoint.
Of those cases reaching the predefined ≥2 g/dL decrease in haemoglobin component of the primary end point in the CONDOR population, 32% of patients were adjudicated as having a non-GI aetiology due to other causes (e.g. flare of their underlying rheumatological disorder).
Who would have adjudicated that?
How, then, can it be adjudicated?
-- and adjudicated the "winner" accordingly.
"We want to see that adjudicated.
We figured it could be adjudicated later".
